2 Biotechs Battling Against Kidney Cancer [The Motley Fool]
Exelixis, Inc. (EXEL)
Last exelixis, inc. earnings: 2/25 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.exelixis.com/phoenix.zhtml?c=120923&p=irol-mediaresources
Company Research
Source: The Motley Fool
The treatment landscape for kidney cancer has undergone a significant shift in the last decade. Between 006 and 009, the U.S. Food and Drug Administration (FDA) approved six drugs for renal cell carcinoma (RCC), the most common form of kidney cancer. A new slate of targeted therapies and immunotherapies arrived on the scene in recent years. The latest approach, combining both types of drugs, has yielded better outcomes for patients than ever before.Image source: Getty Images.A bit of backgoundWe'll get to the drugs, but first, a little about kidney cancer. According to the American Cancer Society, an estimated 7,000 people will be diagnosed with kidney cancer this year, making it a top 0 cancer in the U.S. RCC represents about 8% of all kidney cancers, and is most common in North America and Europe. Drug therapy is typically given for late stages of RCC where surgery is not an option, or following surgery to mop up any lingering cancer cells.Sutent, a drug marketed byPfizerNYSE:PFEExe
Show less
Read more
Impact Snapshot
Event Time:
EXEL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
EXEL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
EXEL alerts
High impacting Exelixis, Inc. news events
Weekly update
A roundup of the hottest topics
EXEL
News
- Exelixis to Webcast Virtual 2025 Research & Development (R&D) Day on Wednesday, December 10, 2025Business Wire
- Exelixis (NASDAQ:EXEL) is now covered by analysts at Wolfe Research. They set a "peer perform" rating on the stock.MarketBeat
- Exelixis, Inc. (EXEL) Presents at Guggenheim Securities 2nd Annual Healthcare Innovation Conference Transcript [Seeking Alpha]Seeking Alpha
- Company News for Nov 6, 2025 [Yahoo! Finance]Yahoo! Finance
- Exelixis: The STELLAR Win Is A Mixed Bag, But Things Look Positive Still [Seeking Alpha]Seeking Alpha
EXEL
Earnings
- 11/4/25 - Beat
EXEL
Sec Filings
- 12/5/25 - Form 4
- 11/26/25 - Form 4
- 11/24/25 - Form 4
- EXEL's page on the SEC website